Bronnen:
Landi D. Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and postpartum in women with MS. Abstract 338. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.
Landi D. Continuation of natalizumab versus interruption is associated with lower risk of relapses during pregnancy and postpartum in women with MS. Abstract 338. ECTRIMS 2019, 11-13 sept 2019, Stockholm, Zweden.